P36 Outcomes of general practitioner prescription of direct acting antiviral therapy utilising a remote consultation referral pathway in Western Victoria

by A.J. Wade, A. McCormack, C. Roder, K. McDonald, M. Wardrop, E. Athan, M.E. Hellard
Published 2017-08-01

O17 Eliminate Hepatitis C Partnership: clinical site scoping

by E. Wong, A. Pedrana, B.L. Draper, J. Gold, J. Richmond, M. Stoove, J.S. Doyle, A.J. Thompson, M.E. Hellard
Published 2017-08-01

O20 Opportunities and challenges experienced when treating HCV in people who inject drugs (PWID) through a nurse-led outreach model

by K. Allardice, S. Von Bibra, J.S. Doyle, P.M. Dietze, P. Desmond, M. Stoove, E. McBryde, P. Higgs, A.J. Thompson, M.E. Hellard
Published 2017-08-01

Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial

by A. J. Wade, J. S. Doyle, E. Gane, C. Stedman, B. Draper, D. Iser, S. K. Roberts, W. Kemp, D. Petrie, N. Scott, P. Higgs, P. A. Agius, J. Roney, L. Stothers, A. J. Thompson, M. E. Hellard
Published 2018-07-01

O5 Hepatitis C elimination in HIV/HCV co-infection through HCV treatment in primary care is feasible and highly effective

by J.S. Doyle, A.L. Bowring, J. Cutts, J. Roney, D.M. Iser, J. Sasadeusz, M. O’Reilly, C. Fairley, E. Gane, J. Hoy, G.V. Matthews, N. Medland, R. Moore, M. Prins, M. Stoové, B.K. Tee, M.E. Hellard
Published 2017-08-01

O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study

by J. Grebely, O. Dalgard, B. Conway, E. Cunningham, P. Bruggmann, B. Hajarizadeh, J. Amin, P. Marks, S. Quiene, T.L. Applegate, T. Swan, J. Byrne, M. Lacalamita, A. Dunlop, J. Bruneau, M.E. Hellard, G.V. Matthews, J. Powis, D. Shaw, M.C. Thurnheer, M. Weltman, I. Kronborg, C. Cooper, J.J. Feld, C. Fraser, A. Litwin, J. Dillon, P. Read, E. Gane, G.J. Dore
Published 2017-08-01